{
    "nctId": "NCT03969693",
    "briefTitle": "Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation",
    "officialTitle": "A Prospective Observational Study With Longitudinal Cardiopulmonary Surveillance in Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Mediastinal Lymphoma, Hodgkin Lymphoma, Non Hodgkin Lymphoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Change in heart function.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with an age of more than 15 years old when encountering local radiotherapy\n* Histologically confirmed Hodgkin lymphoma or non-Hodgkin lymphoma\n* A patient with resected thymoma referred for undergoing postoperative adjuvant radiotherapy is also acceptable and might be feasible\n* The intended radiation field should involve the mediastinum region\n* Malignant lymphoma patients who have undergone systemic chemotherapy with appropriate intensity and cycles tailored to the histologic subtype and oncological staging should start receiving RT within one month after restaging oncological surveys are performed before the course of mediastinal RT. Patient who must complete standard chemotherapy appropriate for the histologic subtype and staging of lymphoma and also be able to start radiation therapy within one month after restaging oncological surveys performed after completing chemotherapy\n* Patients should have a fair to good performance status better than Eastern Cooperative Group (ECOG) of 2.\n* Life expectancy of at least 12 months\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Prior therapeutic radiation therapy delivered to breast, thoracic, or head \\& neck\n* Patients who have a serious medical illness",
    "sex": "ALL",
    "minimumAge": "15 Years",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}